此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study. (ChromoKey)

2026年11月9日 更新者:Kidney Cancer Research Bureau

An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.

Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC.

Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup.

These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

ChromoKey is a prospective, open-label, multicenter, two-cohort, non-randomized phase 2 study evaluating the efficacy and safety of first-line lenvatinib plus pembrolizumab (Cohort A) and later-line lenvatinib plus everolimus (Cohort B) in patients with metastatic chromophobe renal cell carcinoma (chRCC).

The study enrolls 40 patients across two independent cohorts, with 20 patients in each cohort. Eligible patients are adults with histologically confirmed metastatic chRCC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients from all International Metastatic RCC Database Consortium (IMDC) risk groups are eligible.

Cohort A includes patients who have received no previous systemic therapy for metastatic disease. Patients receive lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks.

Cohort B includes patients whose disease progresses following previous systemic therapy and who have not previously received lenvatinib. Patients receive lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily. Treatment continues until disease progression or unacceptable toxicity.

The primary endpoint is the objective response rate in each cohort, defined as the proportion of patients achieving a complete or partial response according to RECIST version 1.1.

Secondary endpoints include progression-free survival, overall survival, duration of response, and safety. Tumor response is evaluated using radiological assessments, and safety is assessed through monitoring of adverse events, clinical examinations, and laboratory investigations.

Each cohort is evaluated independently to characterize the activity and tolerability of the respective combination in its treatment setting. The study does not include randomization or a formal comparison between the two cohorts.

研究类型

介入性

注册 (估计的)

40

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Chelyabinsk、俄罗斯
        • 招聘中
        • Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
        • 接触:
      • Krasnoyarsk、俄罗斯
        • 招聘中
        • V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
        • 接触:
      • Orenburg、俄罗斯
        • 招聘中
        • Orenburg Regional Cancer Center
        • 接触:
      • Saint Petersburg、俄罗斯
        • 招聘中
        • Dr. Berezin Medical Institute
        • 接触:
      • Saint Petersburg、俄罗斯
        • 招聘中
        • SBHI Leningrad regional clinical hospital, Saint-Petersburg
        • 接触:
      • Saratov、俄罗斯
        • 招聘中
        • Saratov Regional Cancer Center
        • 接触:
      • Ufa、俄罗斯
        • 招聘中
        • Republican Clinical Oncology Dispensary
        • 接触:
          • Alexander Sultanbaev
          • 电话号码:+74999054690
          • 邮箱:sten_to@mail.ru
      • Yekaterinburg、俄罗斯
        • 招聘中
        • Sverdlovskiy Regional Oncological Dispensary
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologically confirmed chromophobe renal cell carcinoma.
  • Measurable disease according to RECIST version 1.1.
  • ECOG performance status of 0-3.
  • Cohort A: No prior systemic therapy for metastatic disease.
  • Cohort B: Disease progression following prior systemic therapy and no previous exposure to lenvatinib
  • Adequate bone marrow, hepatic, and renal function.
  • Signed informed consent.

Exclusion Criteria:

  • Uncontrolled or symptomatic central nervous system metastases or leptomeningeal disease.
  • Uncontrolled hypertension despite appropriate antihypertensive treatment.
  • Clinically significant uncontrolled cardiovascular disease.
  • Active infection requiring systemic treatment.
  • Active clinically significant bleeding or a high risk of severe hemorrhage.
  • Major surgery without adequate postoperative recovery or a serious non-healing wound.
  • Gastrointestinal conditions that significantly impair the absorption of oral study medications.
  • Known severe hypersensitivity to any component of the assigned study treatment.
  • Current pneumonitis or interstitial lung disease.
  • Pregnancy or breastfeeding.
  • Any medical or psychiatric condition that, in the investigator's judgment, compromises patient safety or adherence to study procedures.
  • Cohort A only: Active autoimmune disease requiring systemic immunosuppressive treatment, or a requirement for chronic systemic immunosuppression, excluding physiological corticosteroid replacement.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort A: first-line lenvatinib plus pembrolizumab

lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks

tablets

solution

实验性的:Cohort B: later-line lenvatinib plus everolimus

lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily

tablets

tablets

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Objective response rate
大体时间:12 months

the proportion of patients achieving a complete or partial response according to RECIST version 1.1

12 months

次要结果测量

结果测量
措施说明
大体时间
progression-free survival
大体时间:24 months

the time from treatment initiation to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

24 months
overall survival
大体时间:24 months

the time from treatment initiation to death from any cause

24 months
duration of response
大体时间:24 months

the time from the first documented complete or partial response to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first

24 months
Grade 3 and higher treatment-emergent adverse events
大体时间:24 months

the proportion of patients experiencing at least one treatment-emergent adverse event of grade 3 or higher according to NCI CTCAE version 5.0.

24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年8月15日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年12月30日

研究注册日期

首次提交

2026年11月9日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • ChromoKey

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Study results are disseminated through scientific publications and conference presentations in aggregate form.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.